U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 38 results

Status:
US Approved Rx (2024)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)



Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively ...
Status:
US Approved Rx (2014)
First approved in 2000

Class (Stereo):
CHEMICAL (ACHIRAL)



Pantoprazole is a proton pump inhibitor that inhibits gastric acid secretion and used for short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease. Pantoprazole suppresses the final step in gastric acid production b...
Status:
US Approved Rx (1999)
First approved in 1999

Class (Stereo):
CHEMICAL (RACEMIC)



Rabeprazole was discovered by Eisai Co., Ltd. Janssen Pharmaceutica N.V. and Eisai Co., Ltd. have a strategic alliance in which Eisai and Janssen-Cilag co-promote the drug in Germany and the U.K. In the US rabeprazole sodium is co-promoted under the ...
Status:
US Approved Rx (2017)
First approved in 1995

Class (Stereo):
CHEMICAL (RACEMIC)



Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain h...
Status:
US Approved Rx (2016)
First approved in 1989

Class (Stereo):
CHEMICAL (RACEMIC)



Esomeprazole strontium is a proton pump inhibitor. It suppresses gastric acid secretion by specific inhibition H+/K+ ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Linaprazan is a member of a new group of acid-suppressing agents, which unlike proton pump inhibitors, act through potassium-competitive inhibition of the H+,K+-ATPase located in the apical membrane of parietal cells. It displayed rapid inhibition of...
Status:
Other

Class (Stereo):
CHEMICAL (ABSOLUTE)



PF-03716556 is a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. PF-03716556 inhibits the porcine, canine, and human recombinant gastric H+,K+-ATPase in a competitive manner without any biologic...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

SCH-28080 is an inhibitor of H+, K+-ATPase. Administration of SCH-28080 led to significant reduction in the volume, acid output and peptic activity of gastric secretions in a clinical trial.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Sennoside B is a member of the class of sennosides that used as the laxative. Sennosides are used all over the world as a treatment for constipation. Sennosides are hydroxyanthracene glycosides derived from Senna leaves. The phytoconstituents princip...